<DOC>
	<DOCNO>NCT02689089</DOCNO>
	<brief_summary>This phase IV clinical study trial conduct among person require treatment LTBI treatment Iqaluit , Nunavut Ottawa , Ontario . The primary objective study compare proportion people complete directly observe prophylactic treatment ( DOPT ) use new 3HP regimen current standard 9 month INH .</brief_summary>
	<brief_title>Taima TB : 3HP Study</brief_title>
	<detailed_description>The treatment latent tuberculosis infection ( LTBI ) vital component overall strategy reduce TB population . Treatment prevents ongoing transmission community prevent development active TB disease . The current international standard treatment LTBI 9 month Isoniazid ( INH ) . Adherence lengthy regimen one great impediment treatment . A recent multi-centered , multi-national randomize control non inferiority trial approximately 4,000 patient per arm demonstrate Rifapentine INH ( 3HP ) give weekly total 12 dos effective 9 month ( 252 dos ) daily INH treatment LTBI . ( 1 ) These finding also replicate pediatric population pediatric cohort ( n=905 eligible participant ) nest within multi-centered international randomize control trial child age 2-17 treat 3HP compare INH standard LTBI . ( 2 ) The efficacy safety new regimen establish . Rifapentine approve United States Food Drug Administration ( FDA ) December 2014 treatment LTBI yet approve Canada . The shortened treatment course could increase number people complete LTBI treatment could lead decrease active TB case .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Males nonpregnant , nonnursing female age 265 year 2 . LTBI diagnosis per Canadian TB Standards use either Tuberculin Skin Test ( TST ) Interferon Gamma Release Assay ( IGRA ) 3 . Children 25 year negative TSTs close contact case active TB disease recently 4 . Able willing provide fully inform consent parent/guardian able provide consent 1 . Suspected confirm active TB disease 2 . Known allergy study medication participant selfreport 3 . Female participant childbearing potential : 1. positive pregnancy test screening , 2. willing use reliable method barrier contraception study , 3. breastfeed 4 . Unable/unwilling substitute medication drug interaction 3HP , include : 1. hormonal contraception 2 . HIV infect participant antiretroviral drug 3. drug interact 3HP ( see Table 1 ) 5 . Known contact INH rifampin resistant case 6 . Weight &lt; 10 kg 7 . Evidence possible liver damage define aspartate transaminase ( AST ) level 3x upper limit normal asymptomatic patient 8 . Porphyria report patient 9 . Inability adhere protocol . 10 . Patients may exclude study reason , investigator 's discretion detail documentation .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>